Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 12, 2009, Pages 4736-4741

  Araki, Toshiyuki ^a,b   Chan, Gordon ^a,b   Newbigging, Susan ^c   Morikawa, Lily ^c   Bronson, Roderickt ^a   Neel, Benjamin G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Toronto Centre for Phenogenomics   (Canada)

Author keywords

Cardiac development; Cardiac valves; Human disease; Signal transduction protein tyrosine phosphatase

Indexed keywords

K RAS PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; SOS PROTEIN; PROTEIN KINASE B; PTPN11 PROTEIN, MOUSE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; ENDOCARDIUM; EX VIVO STUDY; GENE; GENE MUTATION; HEART DISEASE; HEART MUSCLE; KNOCKOUT MOUSE; MESENCHYME; MOLECULAR MECHANICS; MOUSE; NEURAL CREST; NONHUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TYROSINE PHOSPHATASE SHP 2 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALVULAR HEART DISEASE; ANIMAL; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; ENDOCARDIAL CUSHION; ENZYME ACTIVATION; ENZYMOLOGY; GENE TARGETING; GENETICS; HEART VALVE; MESODERM; METABOLISM; MUTATION; ORGANOGENESIS; PATHOLOGY; PHENOTYPE; PRENATAL DEVELOPMENT;

MUS;

ALLELES; ANIMALS; ENDOCARDIAL CUSHIONS; ENDOCARDIUM; ENZYME ACTIVATION; GENE KNOCK-IN TECHNIQUES; HEART DEFECTS, CONGENITAL; HEART VALVES; MESODERM; MICE; MUTATION; NOONAN SYNDROME; ORGANOGENESIS; PHENOTYPE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 63849250390     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0810053106     Document Type: Article

References (33)

1. Noonan JA (1994) Noonan syndrome. An update and review for the primary pediatrician. Clinical Pediatrics 33:548-555. 2. Tartaglia M, Gelb BD (2005) Noonan syndrome and related disorders: Genetics and pathogenesis. Annual Review of Genomics and Human Genetics 6:45-68.
2. Chan G, Kalaitzidis D, Neel BG (2008) The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 27:179-192.
3. Neel BG, Gu H, Pao L (2003) The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28:284-293.
4. Bentires-Alj M, Kontaridis MI, Neel BG (2006) Stops along the RAS pathway in human genetic disease. Nat Med 12:283-285.
5. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y (2008) The RAS/MAPK syndromes: Novel rolesofthe RASpathwayin human geneticdisorders. HumMutat29:992-1006.
6. Armstrong EJ, Bischoff J (2004) Heart valve development: Endothelial cell signaling and differentiation. Circ Res 95:459-470.
7. Kirby ML, Waldo KL (1995) Neural crest and cardiovascular patterning. Circ Res 77:211-215.
8. Stephen LJ, Fawkes AL, Verhoeve A, Lemke G, Brown A (2007) A critical role for the EphA3 receptor tyrosine kinase in heart development. Dev Biol 302:66-79.
9. Sugi Y, et al. (2003) Fibroblast growth factor (FGF)-4 can induce proliferation of cardiac cushion mesenchymal cells during early valve leaflet formation. Dev Biol 258:252-263.
10. Araki T, et al. (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10:849-857.
11. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG (2005) Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280:30984-30993.
12. Nakamura T, et al. (2007) Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest 117:2123-2132.
13. Gitler AD, et al. (2003) Nf1 has an essential role in endothelial cells. Nat Genet 33:75-79.
14. Newbern J, et al. (2008) Mouse and human phenotypes indicate a critical conserved role forERK2signalingin neural crest development. Proc Natl Acad Sci USA 105:17115-17120.
15. TartagliaM,et al. (2003). SomaticmutationsinPTPN11 injuvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148-150.
16. Gaussin V, et al. (2002) Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc Natl Acad Sci USA 99:2878-2883.
17. de Lange F, et al. (2004)Lineage and morphogenetic analysis of the cardiac valves. Circ Res 95:645-654.
18. Nakajima Y, et al. (1997) Extracellular fibrillar structure of latent TGF beta binding protein-1: Role in TGF beta-dependentendothelial-mesenchymal transformation during endocardial cushion tissue formation in mouseembryonicheart. J Cell Biol 136:193-204.
19. Camenisch TD, Schroeder JA, Bradley J, Klewer SE, McDonald JA (2002) Heart-valve mesenchyme formation isdependenton hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med 8:850-855.
20. Mohammadi M,et al. (1998)Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17:5896-5904.
21. Tartaglia M, et al. (2002) PTPN11 mutations in Noon an syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70:1555-1563.
22. Zenker M, et al. (2004) Genotype-phenotype correlations in Noonan syndrome. J Pediatr (Berlin)144:368-374.
23. Bertola DR, Pereira AC, de Oliveira PS, Kim CA, Krieger JE (2004) Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation. Am J Med Genet A 130A:378-383.
24. Lakkis MM, Epstein JA (1998) Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development (Cambridge, UK) 125:4359-4367.
25. Krenz M, Yutzey KE, Robbins J (2005) Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal- regulated kinase 1/2 signaling. Circ Res 97:813-820.
26. Ha CH, Bennett AM, Jin ZG (2008) A novel role of vascular endothelial cadherin in modulating c-Srcactivation and downstream signaling of vascular endothelial growth factor. J Biol Chem 283:7261-7270.
27. RiethmacherD et al (1997)Severeneuropathiesin mice with targeted mutations in the ErbB3 receptor. Nature 389:725-730.
28. Fukazawa R, et al. (2003) Neuregulin-1 protects ventricular myocytes from anthracy- cline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 35:1473-1479.
29. Kim TE, Murren JR (2002) Erlotinib OSI/Roche/Genentech. Current Opinion in Investigational Drugs 3:1385-1395.
30. Schaefer G, Shao L, Totpal K, Akita RW (2007) Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 67:1228-1238.
31. Rivera-FelicianoJ, et al. (2006) Development of heart valves requires Gata4 expression in endothelial-derived cells. Development 133:3607-3618.
32. Chan G,et al. (2009)Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis. Blood, in press.
33. Krenz M, et al. (2008) Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. Proc Natl Acad Sci USA 105:18930-18935.